Biotech · Private company · Redwood City, CA, US
Adverum Biotechnologies, Inc.
SEC CIK 0001501756
Track this companyFree. Adds Adverum Biotechnologies, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials106 recruiting or active
Pipeline programs11From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline11
- AfliberceptPhase 3 · Neovascular Age-Related Macular Degeneration (nAMD)ClinicalTrials.gov · fetched Nov 12, 2026
- Ixo-vecPhase 3 · Neovascular Age-Related Macular Degeneration (nAMD)ClinicalTrials.gov · fetched Nov 12, 2026
- 2E11 vg/eye of ADVM-022Phase 2 · Diabetic Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
- 6E11 vg/eye of ADVM-022Phase 2 · Diabetic Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
- ADVM-022Phase 2 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- ADVM-043Phase 2 · Alpha 1-Antitrypsin DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- AfliberceptPhase 2 · Diabetic Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
- Ixo-vecPhase 2 · Neovascular Age-Related Macular Degeneration (nAMD) Wet AMDClinicalTrials.gov · fetched Nov 12, 2026
- ADVM-022Phase 1 · Wet Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- ADVM-022Diabetic Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
- No InterventionAlpha-1 Antitrypsin DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular DegenerationPHASE2 · RECRUITING · started Jun 2, 2026ClinicalTrials.gov NCT07630649 · fetched Nov 12, 2026
- Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)PHASE3 · RECRUITING · started Mar 16, 2026ClinicalTrials.gov NCT07482176 · fetched Nov 12, 2026
- Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular DegenerationPHASE3 · ACTIVE_NOT_RECRUITING · started Feb 28, 2025ClinicalTrials.gov NCT06856577 · fetched Nov 12, 2026
- Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]PHASE2 · ACTIVE_NOT_RECRUITING · started Aug 23, 2022ClinicalTrials.gov NCT05536973 · fetched Nov 12, 2026
- Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)ACTIVE_NOT_RECRUITING · started Aug 10, 2022ClinicalTrials.gov NCT05607810 · fetched Nov 12, 2026
- Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]ACTIVE_NOT_RECRUITING · started Dec 14, 2020ClinicalTrials.gov NCT04645212 · fetched Nov 12, 2026
- ADVM-022 Intravitreal Gene Therapy for DMEPHASE2 · COMPLETED · started May 28, 2020ClinicalTrials.gov NCT04418427 · fetched Nov 12, 2026
- Long-Term Follow-up Study of ADVM-043COMPLETED · started Dec 27, 2018ClinicalTrials.gov NCT03804021 · fetched Nov 12, 2026
- ADVM-022 Intravitreal Gene Therapy for Wet AMDPHASE1 · COMPLETED · started Nov 14, 2018ClinicalTrials.gov NCT03748784 · fetched Nov 12, 2026
- Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) DeficiencyPHASE1_PHASE2 · COMPLETED · started Nov 28, 2017ClinicalTrials.gov NCT02168686 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Dec 9, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Dec 4, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 21, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 12, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 24, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 22, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 12, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 12, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 18, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 14, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 14, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 15, 2025 · fetched Nov 12, 2026